Why the study?
Current treatments cannot efficiently prevent doxorubicin-induced cardiotoxicity because its pathogenesis and mechanisms of action remain unknown.
Does doxorubicin induce cardiotoxicity via NF-κB pathway-associated endothelial-to-mesenchymal transition in a rat model?
Does doxorubicin induce cardiotoxicity via NF-κB pathway-associated endothelial-to-mesenchymal transition in a rat model?
Doxorubicin-induced cardiotoxicity involves vascular injury and cardiac fibrosis, potentially driven by NF-κB pathway-associated endothelial-to-mesenchymal transition, highlighting a possible therapeutic target.
Supports NF-κB/EndoMT involvement in doxorubicin cardiotoxicity in rats; hypothesis-generating, leaves open human translation and targeting.
Doxorubicin is a commonly used anthracycline chemotherapeutic agent; however, its application is limited owing to its cardiotoxicity. Current clinical treatments cannot efficiently or fully prevent doxorubicin-induced toxicity, primarily because its pathogenesis and mechanisms of action remain unknown. In this study, we established a rat model of chronic doxorubicin-induced cardiotoxicity, in which the severity of cardiac fibrosis and hydroxyproline levels increased in a time-dependent manner. Doxorubicin damaged the mitochondria and blood vessels and induced autophagy. Cells undergoing endothelial-to-mesenchymal transition (EndoMT)and those expressing endothelial cell and myofibroblast markers were simultaneously observed in vitro and in rats treated with doxorubicin. The NF-κB pathway was activated during EndoMT, andp65 and p-p65 were strongly expressed in the nucleus of endothelial cells in vitro. Taken together, these results suggest that vascular injury and cardiac fibrosis are characteristic symptoms of doxorubicin-induced cardiotoxicity. The NF-κB pathway-associated EndoMT may influence the pathogenesis of doxorubicin-induced cardiotoxicity, and the constituents of this pathway may be potential therapeutic targets to prevent the development of this condition.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: